|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
ES2693232T3
(es)
|
2010-11-30 |
2018-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agente terapéutico que induce citotoxicidad
|
|
KR101572338B1
(ko)
|
2011-02-28 |
2015-11-26 |
에프. 호프만-라 로슈 아게 |
1가 항원 결합 단백질
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CA2833019A1
(en)
|
2011-04-22 |
2012-10-26 |
Emergent Product Development Seattle, Llc |
Prostate-specific membrane antigen binding proteins and related compositions and methods
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2859767C
(en)
*
|
2011-12-19 |
2018-09-11 |
Synimmune Gmbh |
Bispecific antibody molecule and use thereof for treatment of proliferative disease
|
|
US10590202B2
(en)
*
|
2012-11-19 |
2020-03-17 |
Baliopharm Ag |
Recombinant bispecific antibody binding to CD20 and CD95
|
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
EP2958942B1
(en)
|
2013-02-20 |
2020-06-03 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2981822B1
(en)
|
2013-05-06 |
2020-09-02 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
|
EP3024851B1
(en)
|
2013-07-25 |
2018-05-09 |
CytomX Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
|
EP2839842A1
(en)
*
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
KR20160044060A
(ko)
*
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
다중특이적 도메인 교환된 통상의 가변 경쇄 항체
|
|
EP3102681B1
(en)
|
2014-02-07 |
2023-10-04 |
McMaster University |
Trifunctional t cell-antigen coupler and methods and uses thereof
|
|
PT3112462T
(pt)
*
|
2014-02-28 |
2019-02-08 |
Astellas Pharma Inc |
Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humano
|
|
WO2015134411A1
(en)
*
|
2014-03-03 |
2015-09-11 |
Academia Sinica |
Bi-specific antibodies and uses thereof
|
|
CN106459206B
(zh)
|
2014-04-07 |
2024-06-07 |
中外制药株式会社 |
免疫活化抗原结合分子
|
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
|
JP6822849B2
(ja)
*
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的ＮＫｐ４６結合タンパク質
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
CN104558192B
(zh)
*
|
2015-01-21 |
2018-12-28 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体her2xcd3的构建及应用
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
WO2016011571A1
(en)
*
|
2014-07-21 |
2016-01-28 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
|
|
US10669337B2
(en)
|
2014-07-25 |
2020-06-02 |
Cytomx Therapeutics, Inc. |
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
EP2985294A1
(en)
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
|
WO2016028896A1
(en)
|
2014-08-19 |
2016-02-25 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
JP6796059B2
(ja)
|
2014-09-12 |
2020-12-02 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｗｎｔシグナリングアゴニスト分子
|
|
EP3218005B1
(en)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
AU2015346205B2
(en)
*
|
2014-11-12 |
2021-07-29 |
Memorial Sloan Kettering Cancer Center |
Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2016086189A2
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
SG11201704274QA
(en)
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
|
DK3240805T3
(da)
|
2014-12-15 |
2025-02-10 |
Univ California |
Bispecifik or-gate kimærisk antigenreceptor, som reagerer på cd19 og cd20
|
|
KR102548827B1
(ko)
*
|
2014-12-22 |
2023-06-30 |
시스트이뮨, 인코포레이티드 |
이중특이적 4가 항체 및 이의 제조 및 사용방법
|
|
CN105821029A
(zh)
*
|
2015-01-04 |
2016-08-03 |
彭霞 |
异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
|
|
CN104788567B
(zh)
*
|
2015-01-21 |
2019-03-26 |
武汉友芝友生物制药有限公司 |
一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用
|
|
CN104592391B
(zh)
*
|
2015-01-21 |
2020-08-21 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体EpCAM×CD3的构建及应用
|
|
CN104558193B
(zh)
*
|
2015-01-21 |
2019-01-11 |
武汉友芝友生物制药有限公司 |
一种靶向鼠t淋巴细胞cd3和人肿瘤抗原her2的双特异性抗体制备方法及应用
|
|
CN104628866B
(zh)
*
|
2015-01-21 |
2018-03-27 |
中国药科大学 |
一种靶向vegfr2的抗体融合蛋白的制备及其用途
|
|
CN104774268B
(zh)
*
|
2015-01-21 |
2018-09-28 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体egfr×cd3的构建及应用
|
|
CN104592395B
(zh)
*
|
2015-01-27 |
2017-11-14 |
中国药科大学 |
Vegfr2单链抗体与mica融合蛋白的制备方法及用途
|
|
WO2016207867A1
(en)
|
2015-02-25 |
2016-12-29 |
Université Du Luxembourg |
Nat8l and n-acetylaspartate in cancer
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
RU2754661C2
(ru)
|
2015-05-01 |
2021-09-06 |
Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния |
Гликанзависимые иммунотерапевтические молекулы
|
|
MY189692A
(en)
*
|
2015-05-07 |
2022-02-26 |
Memorial Sloan Kettering Cancer Center |
Anti-ox40 antibodies and methods of use thereof
|
|
WO2017011342A1
(en)
*
|
2015-07-10 |
2017-01-19 |
Abbvie Inc. |
Igm-or-ige-modified binding proteins and uses thereof
|
|
TWI829617B
(zh)
*
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
*
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
JP6622396B2
(ja)
|
2015-08-26 |
2019-12-18 |
バイソン セラピュイティクス インコーポレイテッド |
多重特異性抗体プラットフォームおよびその関連方法
|
|
LU92815B1
(en)
|
2015-09-04 |
2017-03-20 |
Univ Luxembourg |
Inhibitor of dj-1 for therapy
|
|
BR112018005573A2
(pt)
|
2015-09-21 |
2019-01-22 |
Aptevo Research And Development Llc |
?polipeptídeos de ligação a cd3?
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
MY198560A
(en)
|
2015-10-02 |
2023-09-05 |
Hoffmann La Roche |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
WO2017060144A1
(en)
*
|
2015-10-07 |
2017-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory tnf receptor
|
|
EP3362479A4
(en)
|
2015-10-13 |
2019-05-15 |
Eureka Therapeutics, Inc. |
FOR HUMANESE CD19 SPECIFIC ANTIBODY AGENTS AND USES THEREOF
|
|
MX2018005232A
(es)
|
2015-11-03 |
2018-08-15 |
Ambrx Inc |
Anticuerpos anti-cd3 novedosos y sus usos.
|
|
JP7066613B2
(ja)
|
2015-11-12 |
2022-05-13 |
シージェン インコーポレイテッド |
グリカン相互作用化合物および使用方法
|
|
WO2017081190A1
(en)
*
|
2015-11-13 |
2017-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
IL299072A
(en)
|
2015-12-02 |
2023-02-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies and methods of use thereof
|
|
EP3192810A1
(en)
*
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
MY195542A
(en)
|
2016-02-03 |
2023-01-31 |
Amgen Res Munich Gmbh |
Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
CA3015162A1
(en)
|
2016-03-15 |
2017-09-21 |
Cancer Research Technology Limited |
Antibodies and related molecules and uses thereof
|
|
JP7082604B2
(ja)
*
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
|
EP3439699A4
(en)
*
|
2016-04-04 |
2019-11-20 |
Hemogenyx LLC |
METHOD FOR ELIMINATING HEMATOPOETIC STEM CELLS / HEMATOPOIDIC PRECURSOR CELLS (HSC / HP) IN A PATIENT WITH BI-SPECIFIC ANTIBODIES
|
|
US11104738B2
(en)
|
2016-04-04 |
2021-08-31 |
Hemogenyx Pharmaceuticals Llc |
Monoclonal antibodies to human FLT3/FLK2 receptor protein
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
CN107556388A
(zh)
*
|
2016-06-30 |
2018-01-09 |
中国科学院深圳先进技术研究院 |
抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
|
|
GB201611530D0
(en)
*
|
2016-07-01 |
2016-08-17 |
Alligator Bioscience Ab |
Novel polypeptides
|
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
US20200017588A1
(en)
*
|
2016-10-14 |
2020-01-16 |
Dana-Farber Cancer Institute, Inc. |
Modular tetravalent bispecific antibody platform
|
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
|
JP7122311B2
(ja)
|
2017-01-03 |
2022-08-19 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗４－１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子
|
|
US20200095327A1
(en)
*
|
2017-02-08 |
2020-03-26 |
Dragonfly Therapeutics, Inc. |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
|
KR20250089564A
(ko)
*
|
2017-02-08 |
2025-06-18 |
드래곤플라이 쎄라퓨틱스, 인크. |
천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
|
|
KR20190120782A
(ko)
|
2017-02-20 |
2019-10-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Her2, nkg2d 및 cd16에 결합하는 단백질
|
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
CN113201071A
(zh)
*
|
2017-03-28 |
2021-08-03 |
礼进生物医药科技（上海）有限公司 |
用于增强肿瘤微环境中免疫应答的治疗剂和方法
|
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
WO2018178055A1
(en)
*
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
US11807662B2
(en)
*
|
2017-05-16 |
2023-11-07 |
The Johns Hopkins University |
MANAbodies and methods of using
|
|
CA3064714A1
(en)
*
|
2017-05-23 |
2018-11-29 |
Dragonfly Therapeutics, Inc. |
A protein binding nkg2d, cd16 and a tumor-associated antigen
|
|
CN108948195B
(zh)
*
|
2017-05-23 |
2022-05-31 |
胡毅 |
一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
|
|
JP7234142B2
(ja)
*
|
2017-06-02 |
2023-03-07 |
ファイザー・インク |
Ｆｌｔ３に特異的な抗体およびその使用
|
|
CN119899277A
(zh)
|
2017-06-02 |
2025-04-29 |
辉瑞公司 |
靶向flt3的嵌合抗原受体
|
|
WO2019023097A1
(en)
*
|
2017-07-26 |
2019-01-31 |
Smet Pharmaceutical Inc |
ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
|
|
WO2019028027A1
(en)
*
|
2017-07-31 |
2019-02-07 |
Dragonfly Therapeutics, Inc. |
PROTEINS BINDING TO NKG2D, CD16 AND FLT3
|
|
AU2018331430A1
(en)
|
2017-09-13 |
2020-03-19 |
Radimmune Therapeutics, Inc. |
Melanin antibodies and uses thereof
|
|
CN111788225B
(zh)
*
|
2017-10-10 |
2025-02-18 |
赛诺菲 |
抗cd38抗体及与抗cd3和抗cd28抗体的组合
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
JP7317016B2
(ja)
|
2017-12-19 |
2023-07-28 |
スロゼン オペレーティング， インコーポレイテッド |
抗ｌｒｐ５／６抗体及び使用方法
|
|
AU2018393073B2
(en)
|
2017-12-19 |
2025-09-18 |
Surrozen Operating, Inc. |
Wnt surrogate molecules and uses thereof
|
|
US12006368B2
(en)
|
2017-12-19 |
2024-06-11 |
Surrozen Operating, Inc. |
Anti-frizzled antibodies and methods of use
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
PE20210375A1
(es)
|
2018-02-08 |
2021-03-02 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019175368A1
(en)
|
2018-03-14 |
2019-09-19 |
Affimed Gmbh |
Bispecific egfr/cd16 antigen-binding protein
|
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
WO2019222449A1
(en)
*
|
2018-05-16 |
2019-11-21 |
Dragonfly Therapeutics, Inc. |
Protein binding nkg2d, cd16 and a fibroblast activation protein
|
|
CA3100349A1
(en)
*
|
2018-05-17 |
2019-11-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor inhibition by phosphatase recruitment
|
|
EA202091977A1
(ru)
*
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
|
CN110540593B
(zh)
*
|
2018-05-29 |
2022-05-17 |
上海药明生物技术有限公司 |
新型的抗cd3/抗cd20双特异性抗体
|
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
|
MX2020013606A
(es)
|
2018-06-14 |
2021-05-27 |
Bioatla Inc |
Constructos de anticuerpos multiespecificos.
|
|
US20210269499A1
(en)
|
2018-06-21 |
2021-09-02 |
Technische Universitaet Muenchen |
Hepatitis b and/or hepatitis d-permissive cells and animals
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
US10640562B2
(en)
*
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
WO2020018727A1
(en)
*
|
2018-07-17 |
2020-01-23 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
BR112021002276A2
(pt)
|
2018-08-08 |
2021-05-04 |
Dragonfly Therapeutics, Inc. |
proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
KR102884943B1
(ko)
*
|
2018-09-11 |
2025-11-12 |
도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 |
개선된 항-flt3 항원 결합 단백질
|
|
EP3623383A1
(en)
|
2018-09-11 |
2020-03-18 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Improved bispecific flt3xcd3 antigen binding proteins
|
|
EP3880247A4
(en)
*
|
2018-11-13 |
2022-10-26 |
JN Biosciences, LLC |
Bispecific antibodies for activation of immune cells
|
|
MY198034A
(en)
*
|
2018-12-21 |
2023-07-27 |
Hoffmann La Roche |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
WO2020132810A1
(en)
*
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
US11912767B2
(en)
|
2019-03-22 |
2024-02-27 |
Regeneron Pharmaceuticals, Inc. |
EGFR × CD28 multispecific antibodies
|
|
CN114008078B
(zh)
*
|
2019-05-06 |
2025-05-30 |
布朗大学 |
具有增强的t细胞介导的对肿瘤细胞的细胞毒性作用的针对chi3l1和pd1的双特异性抗体
|
|
US11667712B2
(en)
*
|
2019-05-08 |
2023-06-06 |
Janssen Biotech, Inc. |
Materials and methods for modulating t cell mediated immunity
|
|
CN115298217A
(zh)
*
|
2019-10-15 |
2022-11-04 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16及flt3的蛋白质
|
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
CA3163023A1
(en)
*
|
2020-01-09 |
2021-07-15 |
Olivier Lantz |
Multispecific antibodies that bind both mait and tumor cells
|
|
CN113088495B
(zh)
*
|
2020-01-09 |
2024-08-16 |
苏州方德门达新药开发有限公司 |
工程改造的t细胞、其制备及应用
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
WO2021183845A1
(en)
*
|
2020-03-13 |
2021-09-16 |
Janssen Biotech, Inc. |
Materials and methods for modulating delta chain mediated immunity
|
|
WO2021207681A1
(en)
*
|
2020-04-10 |
2021-10-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted reduction of activated immune cells
|
|
US12157771B2
(en)
|
2020-05-06 |
2024-12-03 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
JP7678005B2
(ja)
*
|
2020-06-23 |
2025-05-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ２を標的とするアゴニストＣＤ２８抗原結合分子
|
|
KR20230166150A
(ko)
*
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
EP4237003A4
(en)
|
2020-10-28 |
2025-07-09 |
Janssen Biotech Inc |
COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
|
|
MX2023005063A
(es)
*
|
2020-11-02 |
2023-05-12 |
Attralus Inc |
Proteinas de fusion sap fc y metodos de uso.
|
|
AU2021374803A1
(en)
|
2020-11-03 |
2023-06-22 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
WO2022180145A2
(en)
|
2021-02-26 |
2022-09-01 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
CA3173810A1
(en)
|
2021-06-01 |
2022-12-01 |
Andreas Bader |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CA3252619A1
(en)
|
2022-02-23 |
2023-08-31 |
Xencor, Inc. |
Anti-CD28 and anti-PSMA antibodies
|
|
TW202417056A
(zh)
|
2022-08-29 |
2024-05-01 |
日商第一三共股份有限公司 |
包含變異Fc區域的抗體藥物結合物
|
|
CN120693344A
(zh)
|
2023-02-14 |
2025-09-23 |
德国癌症研究公共权益基金会 |
具有改善的特性的il-15融合蛋白
|
|
EP4527851A1
(en)
|
2023-09-22 |
2025-03-26 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding ltbr and lrrc15
|
|
WO2025147512A1
(en)
*
|
2024-01-02 |
2025-07-10 |
Eli Lilly And Company |
Immunogenicity assessment platform for biotherapeutic proteins
|
|
WO2025185760A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Itabmed Biopharmaceutical (Shanghai) Co., Ltd. |
Multispecific antigen binding proteins and uses thereof
|